Stockscreener 앱 받기
0.8468
0.13%
-0.0011
시간 외 거래:
.86
0.0132
+1.56%
전일 마감가:
$0.8479
열려 있는:
$0.8478
하루 거래량:
50,980
Relative Volume:
0.12
시가총액:
$7.38M
수익:
$3.95M
순이익/손실:
$-14.59M
주가수익비율:
-0.7284
EPS:
-1.1626
순현금흐름:
$-14.46M
1주 성능:
+4.67%
1개월 성능:
-4.60%
6개월 성능:
-28.42%
1년 성능:
-40.78%
1일 변동 폭
$0.829
$0.8657
1주일 범위
$0.7699
$0.9051
52주 변동 폭
$0.73
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.8468 | 7.39M | 3.95M | -14.59M | -14.46M | -1.1626 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-08 | 개시 | ROTH Capital | Buy |
| 2021-07-29 | 개시 | Aegis Capital | Buy |
| 2020-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 개시 | Oppenheimer | Outperform |
Evogene Ltd 주식(EVGN)의 최신 뉴스
Evogene (EVGN) director Leon Recanati details share and option holdings - Stock Titan
Evogene (EVGN) director Nir details multiple stock option grants in Form 3 - Stock Titan
Evogene (EVGN) director details stock option grants and vesting - Stock Titan
Evogene (EVGN) chief development officer reports 40,000-share stock option grant - Stock Titan
[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Evogene (EVGN) director Sarit Firon details long-dated stock option grants - Stock Titan
Evogene (EVGN) CFO details RSU and stock option holdings - Stock Titan
Evogene (EVGN) CEO Haviv Ofer details multi-year stock option grants - Stock Titan
Evogene Ltd Stock (ISIN: IL0010831684) Faces Biotech Volatility Amid AI-Driven Crop Innovation Push - AD HOC NEWS
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Evogene outlines ChemPass AI-driven strategy and anticipates new collaborations amid organizational realignment - MSN
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm
Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Evogene Earnings Call: AI Ambition Meets Cash Reality - The Globe and Mail
Evogene Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Evogene Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Evogene: Q4 Earnings Snapshot - theheraldreview.com
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains - Investing.com
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains By Investing.com - Investing.com India
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Evogene Reports Fourth Quarter and Full Year 2025 Financial Resu - GuruFocus
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks
EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative
Evogene Earnings Review: Q4 Summary - Benzinga
An Overview of Evogene's Earnings - Benzinga
Evogene Ltd expected to post a loss of 26 cents a shareEarnings Preview - TradingView
EVGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EVGN Should I Buy - Intellectia AI
Is Evogene Ltd. stock heavily shortedJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Evogene refocuses on AI drug discovery platform ChemPass By Investing.com - Investing.com India
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - The Globe and Mail
Evogene refocuses on AI drug discovery platform ChemPass - Investing.com
Evogene Releases CEO Letter to Shareholders - Finviz
Evogene substantially completed divestment of non-core subsidiaries - marketscreener.com
Evogene (EVGN) pivots to ChemPass AI and core health and ag markets - Stock Titan
Fund Flows: Does Evogene Ltd have consistent dividend growth2025 Market WrapUp & AI Based Trade Execution Alerts - baoquankhu1.vn
Winners Losers: Is ProShares Trust ProShares UltraShort Consumer Staples likely to announce a buybackWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CEO Moves: Is Evogene Ltd in a consolidation phaseJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release – Company Announcement - Financial Times
Evogene and QUT partner on AI-based cancer therapies - Pharmaceutical Business review -
Ideas Watch: Is Huntington Ingalls Industries Inc a good stock for dollar cost averaging2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - Nasdaq
Will Evogene Ltd. stock hit new highs in YEARBear Alert & Accurate Entry/Exit Alerts - mfd.ru
Why did EVGN shares drop more than 14% today? - MSN
Evogene Ltd (EVGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):